NEWS
Sheffield relocation for UK NEQAS
UK National External Quality Assessment Service (UK NEQAS) is to relocate its Sheffield site to Sheffield Olympic Legacy Park and its state-of-the-art incubation centre, Landing Pad. The move for UK NEQAS will help propel the Park further towards becoming a global centre of excellence for innovation in health, sport and wellbeing.
Renowned for its proficiency testing services and quality assessment programmes, UK NEQAS’ strategic decision to relocate to Sheffield Olympic Legacy Park is aligned with its vision to foster innovation,
Breakthrough for Roche’s Alzheimer’s blood test
Roche’s Elecsys pTau217 assay blood test, which is being developed in collaboration with Eli Lilly, has received Breakthrough Device Designation from the US Food and Drug Administration (FDA). The test aids in identifying amyloid pathology, a key feature of Alzheimer’s disease, and the two firms believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis. If approved, the test could help
rapidly broaden access to a more timely and accurate diagnosis and potentially mitigate the impact of Alzheimer’s disease on people and society. Identifying the presence or absence of amyloid pathology in individuals can help ensure they are able to receive appropriate care. This may include participation in clinical trials or access to approved disease-modifying therapies.
Matt Sause, CEO of Roche Diagnostics, commented: “We believe pTau217 is going to be crucial in the diagnosis of Alzheimer’s disease, a condition where Roche Diagnostics is committed to improving the lives of patients worldwide. We plan to leverage our installed base of diagnostic systems, which is the largest in the world, to ensure we are able to create access to this test for those who need it the most.” pTau217, which is a phosphorylated fragment of the protein tau, is a biomarker that has shown the ability in research settings to distinguish Alzheimer’s disease from other neurodegenerative disorders.
WWW.PATHOLOGYINPRACTICE.COM MAY 2024 11
collaboration and growth within the healthcare community. Previously based at the Northern General Hospital, UK NEQAS’s Sheffield base joins a growing number of health, sport and wellbeing focused organisations based within the flex office space at Landing Pad, including Barnsley Women’s FC, Cricket Arena, Reyt and, most recently, Medilink North.
Jen Christie at UK NEQAS commented:
“We’re extremely excited to be relocating UK NEQAS to Landing Pad. The state-of-
the-art facilities offered onsite will no doubt increase the opportunities for us to fulfil our charity aims of improving healthcare through education, as well as fostering the creation and delivery of new and innovative services. We can’t wait to move in!” UK NEQAS has taken a four-year licence
on a four-person private suite at Landing Pad and expects to be up and running by the end of May 2024.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
